Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

doi:10.1056/NEJM199604113341502

Volume 334:939-945		April 11, 1996		Number 15

Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

Giuseppe Maschio, M.D., Daniele Alberti, M.D., Gérard Janin, M.D., Francesco Locatelli, M.D., Johannes F.E. Mann, M.D., Mario Motolese, M.D., Claudio Ponticelli, M.D., Eberhard Ritz, M.D., Pietro Zucchelli, M.D., for The Angiotensin-Converting–Enzyme Inhibition in Progressive Renal Insufficiency Study Group

Full Text

PDF

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Background Drugs that inhibit angiotensin-converting enzymeslow the progression of renal insufficiency in patients withdiabetic nephropathy. Whether these drugs have a similar actionin patients with other renal diseases is not known. We conducteda study to determine the effect of the angiotensin-converting–enzymeinhibitor benazepril on the progression of renal insufficiencyin patients with various underlying renal diseases.

Methods In a three-year trial involving 583 patients with renalinsufficiency caused by various disorders, 300 patients receivedbenazepril and 283 received placebo. The underlying diseasesincluded glomerulopathies (in 192 patients), interstitial nephritis(in 105), nephrosclerosis (in 97), polycystic kidney disease(in 64), diabetic nephropathy (in 21), and miscellaneous orunknown disorders (in 104). The severity of renal insufficiencywas classified according to the base-line creatinine clearance:227 patients had mild insufficiency (creatinine clearance, 46to 60 ml per minute), and 356 had moderate insufficiency (creatinineclearance, 30 to 45 ml per minute). The primary end point wasa doubling of the base-line serum creatinine concentration orthe need for dialysis.

Results At three years, 31 patients in the benazepril groupand 57 in the placebo group had reached the primary end point(P<0.001). In the benazepril group, the reduction in therisk of reaching the end point was 53 percent overall (95 percentconfidence interval, 27 to 70 percent), 71 percent (95 percentconfidence interval, 21 to 90 percent) among the patients withmild renal insufficiency, and 46 percent (95 percent confidenceinterval, 12 to 67 percent) among those with moderate renalinsufficiency. The reduction in risk was greatest among themale patients; those with glomerular diseases, diabetic nephropathy,or miscellaneous or unknown causes of renal disease; and thosewith base-line urinary protein excretion above 1 g per 24 hours.Benazepril was not effective in patients with polycystic disease.Diastolic pressure decreased by 3.5 to 5.0 mm Hg in the benazeprilgroup and increased by 0.2 to 1.5 mm Hg in the placebo group.

Conclusions Benazepril provides protection against the progressionof renal insufficiency in patients with various renal diseases.

Source Information

From the Divisione di Nefrologia, Ospedale Civile, Verona, Italy (G.M.); the Medical Department, Ciba–Geigy, Origgio, Italy (D.A., M.M.); the Service d'Hémodialyse, Hôpital des Chanaux, Mâcon, France (G.J.); the Divisione di Nefrologia, Ospedale di Lecco, Lecco, Italy (F.L.); the VI Medizinische Abteilung, Staedtisches Klinikum Schwabing, and the German Institute for High Blood Pressure Research, Munich, Germany (J.F.E.M.); the Divisione di Nefrologia e Dialisi, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Maggiore Policlinico, Milan, Italy (C.P.); the Rehabilitationszentrum für Chronisch Nierenkranke, Universitätsklinik Heidelberg, Heidelberg, Germany (E.R.); and the Divisione di Nefrologia e Dialisi, Servizio Ospedaliero S. Orsola, Malpighi, Bologna, Italy (P.Z.).

Address reprint requests to Dr. Maschio at the Divisione di Nefrologia, Ospedale Civile, I-37126, Verona, Italy.

Full Text of this Article

Related Letters:

Effect of Benazepril in Chronic Renal Insufficiency
Apperloo A. J., Rensma P. L., Curren C. G., Maschio G., Alberti D., Locatelli F.
Extract | Full Text
N Engl J Med 1996; 335:596-598, Aug 22, 1996. Correspondence

This article has been cited by other articles:

Ku, E., Park, J., Vidhun, J., Campese, V. (2009). The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease. Arch Intern Med 169: 1015-1018 [Full Text]
O'Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., Larson, E. B. (2009). Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?. ANN INTERN MED 150: 717-724 [Abstract] [Full Text]
Proesmans, W., Van Dyck, M., Devriendt, K. (2009). Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment. Nephrol Dial Transplant 24: 1335-1338 [Abstract] [Full Text]
Nuzum, D. S., Merz, T. (2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice 22: 135-148 [Abstract]
Harita, Y., Kurihara, H., Kosako, H., Tezuka, T., Sekine, T., Igarashi, T., Ohsawa, I., Ohta, S., Hattori, S. (2009). Phosphorylation of Nephrin Triggers Ca2+ Signaling by Recruitment and Activation of Phospholipase C-{gamma}1. J. Biol. Chem. 284: 8951-8962 [Abstract] [Full Text]
Sugiura, T., Wada, A. (2009). Resistive index predicts renal prognosis in chronic kidney disease. Nephrol Dial Transplant 0: gfp121v1-gfp121 [Abstract] [Full Text]
Ovbiagele, B. (2009). Medications Impair Kidney Function in Stroke Population--Reply. Arch Neurol 66: 416-416 [Full Text]
Rizk, D., Jurkovitz, C., Veledar, E., Bagby, S., Baumgarten, D. A., Rahbari-Oskoui, F., Steinman, T., Chapman, A. B. (2009). Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients not yet on Dialysis. CJASN 4: 560-566 [Abstract] [Full Text]
Fried, L. F., Duckworth, W., Zhang, J. H., O'Connor, T., Brophy, M., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S., Warren, S. R., Peduzzi, P., for VA NEPHRON-D Investigators, (2009). Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). CJASN 4: 361-368 [Abstract] [Full Text]
Saran, A. M., DuBose, T. D. Jr (2008). Cardiovascular disease in chronic kidney disease. Ther Adv Cardiovasc Dis 2: 425-434 [Abstract]
Luks, A. M., Johnson, R. J., Swenson, E. R. (2008). Chronic Kidney Disease at High Altitude. J. Am. Soc. Nephrol. 19: 2262-2271 [Abstract] [Full Text]
HIRSCH, S. (2008). An update on proteinuric chronic kidney disease: The dual-goal approach. Cleveland Clinic Journal of Medicine 75: 705-713 [Abstract] [Full Text]
Izuhara, Y., Sada, T., Yanagisawa, H., Koike, H., Ohtomo, S., Dan, T., Ito, S., Nangaku, M., van Ypersele de Strihou, C., Miyata, T. (2008). A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats. Arterioscler. Thromb. Vasc. Bio. 28: 1767-1773 [Abstract] [Full Text]
Ovbiagele, B. (2008). Impairment in Glomerular Filtration Rate or Glomerular Filtration Barrier and Occurrence of Stroke. Arch Neurol 65: 934-938 [Abstract] [Full Text]
Chapman, A. B. (2008). Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies. CJASN 3: 1197-1204 [Abstract] [Full Text]
Wehner, A., Hartmann, K., Hirschberger, J. (2008). Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal diseases. Vet Rec. 162: 141-147 [Abstract] [Full Text]
Zeltner, R., Poliak, R., Stiasny, B., Schmieder, R. E., Schulze, B. D. (2008). Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 573-579 [Abstract] [Full Text]
Steinman, T. I. (2008). Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 431-433 [Full Text]
Lely, A. T., van der Kleij, F. G.H., Kistemaker, T. J., Apperloo, A. J., de Jong, P. E., de Zeeuw, D., Navis, G. (2008). Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention. CJASN 3: 54-60 [Abstract] [Full Text]
Linas, S. L. (2008). Managing CKD: Key Therapeutic Issues Introduction. CJASN 3: S1-S2 [Full Text]
Bakris, G. L. (2008). Slowing Nephropathy Progression: Focus on Proteinuria Reduction. CJASN 3: S3-S10 [Abstract] [Full Text]
Burnier, M. (2007). Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective. Journal of Renin-Angiotensin-Aldosterone System 8: 208-211
Reich, H. N., Troyanov, S., Scholey, J. W., Cattran, D. C., for the Toronto Glomerulonephritis Registry, (2007). Remission of Proteinuria Improves Prognosis in IgA Nephropathy. J. Am. Soc. Nephrol. 18: 3177-3183 [Abstract] [Full Text]
Dhaun, N., Ferro, C. J., Davenport, A. P., Haynes, W. G., Goddard, J., Webb, D. J. (2007). Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 22: 3228-3234 [Abstract] [Full Text]
Siragy, H. M. (2007). Angiotensin AT1 and AT2 receptors the battle for health and disease. Nephrol Dial Transplant 22: 3128-3130 [Full Text]
Velez, J. C. Q., Bland, A. M., Arthur, J. M., Raymond, J. R., Janech, M. G. (2007). Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am. J. Physiol. Renal Physiol. 293: F398-F407 [Abstract] [Full Text]
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., Levey, A. S., for the AIRPD Study Group, (2007). Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. J. Am. Soc. Nephrol. 18: 1959-1965 [Abstract] [Full Text]
Hou, F. F., Xie, D., Zhang, X., Chen, P. Y., Zhang, W. R., Liang, M., Guo, Z. J., Jiang, J. P. (2007). Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency. J. Am. Soc. Nephrol. 18: 1889-1898 [Abstract] [Full Text]
Coppo, R., Peruzzi, L., Amore, A., Piccoli, A., Cochat, P., Stone, R., Kirschstein, M., Linne, T., on behalf of the EC Biomed Concerted Action Projec, (2007). IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria. J. Am. Soc. Nephrol. 18: 1880-1888 [Abstract] [Full Text]
Mizobuchi, M., Morrissey, J., Finch, J. L., Martin, D. R., Liapis, H., Akizawa, T., Slatopolsky, E. (2007). Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Vitamin D Analog Suppresses the Progression of Renal Insufficiency in Uremic Rats. J. Am. Soc. Nephrol. 18: 1796-1806 [Abstract] [Full Text]
Suzuki, K., Han, G. D., Miyauchi, N., Hashimoto, T., Nakatsue, T., Fujioka, Y., Koike, H., Shimizu, F., Kawachi, H. (2007). Angiotensin II Type 1 and Type 2 Receptors Play Opposite Roles in Regulating the Barrier Function of Kidney Glomerular Capillary Wall. Am. J. Pathol. 170: 1841-1853 [Abstract] [Full Text]
Zandi, M. S, Coles, A. J (2007). Notes on the kidney and its diseases for the neurologist. J. Neurol. Neurosurg. Psychiatry 78: 444-449 [Abstract] [Full Text]
Hingorani, A. P., Ascher, E., Marks, N. (2007). Duplex Arteriography for Lower Extremity Revascularization. PERSPECT VASC SURG ENDOVASC THER 19: 6-20 [Abstract]
Schiffmann, R. (2007). Enzyme Replacement in Fabry Disease: The Essence Is in the Kidney. ANN INTERN MED 146: 142-144 [Full Text]
Kamper, A.-L. (2007). The importance of a correct evaluation of progression in studies on chronic kidney disease. Nephrol Dial Transplant 22: 3-5 [Full Text]
Jose, P., Skali, H., Anavekar, N., Tomson, C., Krumholz, H. M., Rouleau, J. L., Moye, L., Pfeffer, M. A., Solomon, S. D., for the SAVE Investigators, (2006). Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. J. Am. Soc. Nephrol. 17: 2886-2891 [Abstract] [Full Text]
Griffin, K. A., Bidani, A. K. (2006). Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade. CJASN 1: 1054-1065 [Abstract] [Full Text]
van Bemmel, T., Woittiez, K., Blauw, G. J., van der Sman-de Beer, F., Dekker, F. W., Westendorp, R. G.J., Gussekloo, J. (2006). Prospective Study of the Effect of Blood Pressure on Renal Function in Old Age: The Leiden 85-Plus Study. J. Am. Soc. Nephrol. 17: 2561-2566 [Abstract] [Full Text]
Lubrano, R., Soscia, F., Elli, M., Ventriglia, F., Raggi, C., Travasso, E., Scateni, S., Di Maio, V., Versacci, P., Masciangelo, R., Romero, S. (2006). Renal and Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitor Plus Angiotensin II Receptor Antagonist Therapy in Children With Proteinuria. Pediatrics 118: e833-e838 [Abstract] [Full Text]
Jones, C., Roderick, P., Harris, S., Rogerson, M. (2006). Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 21: 2133-2143 [Abstract] [Full Text]
Djamali, A., Samaniego, M., Muth, B., Muehrer, R., Hofmann, R. M., Pirsch, J., Howard, A., Mourad, G., Becker, B. N. (2006). Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. CJASN 1: 623-640 [Abstract] [Full Text]
Ponda, M. P., Hostetter, T. H. (2006). Aldosterone Antagonism in Chronic Kidney Disease. CJASN 1: 668-677 [Full Text]
Oudit, G. Y., Herzenberg, A. M., Kassiri, Z., Wong, D., Reich, H., Khokha, R., Crackower, M. A., Backx, P. H., Penninger, J. M., Scholey, J. W. (2006). Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis. Am. J. Pathol. 168: 1808-1820 [Abstract] [Full Text]
Bloom, J. M., Jaber, B. L., Madias, N. E., Hou, F. F., Zhang, X. (2006). Benazepril for advanced chronic renal insufficiency.. NEJM 354: 1530-1531 [Full Text]
Chrysostomou, A., Pedagogos, E., MacGregor, L., Becker, G. J. (2006). Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker. CJASN 1: 256-262 [Abstract] [Full Text]
Liebau, M. C., Lang, D., Bohm, J., Endlich, N., Bek, M. J., Witherden, I., Mathieson, P. W., Saleem, M. A., Pavenstadt, H., Fischer, K.-G. (2006). Functional expression of the renin-angiotensin system in human podocytes. Am. J. Physiol. Renal Physiol. 290: F710-F719 [Abstract] [Full Text]
Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J.V., Yusuf, S., Granger, C. B., Michelson, E. L., Ostergren, J., Cornel, J. H., de Zeeuw, D., Pocock, S., van Veldhuisen, D. J., on behalf of the Candesartan in Heart Failure: Ass, (2006). Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation 113: 671-678 [Abstract] [Full Text]
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., Geng, R. W. (2006). Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency. NEJM 354: 131-140 [Abstract] [Full Text]
Berl, T., Henrich, W. (2006). Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. CJASN 1: 8-18 [Full Text]
Tse, K C, Li, F K, Tang, S, Tang, C S-O, Lai, K N, Chan, T M (2005). Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14: 947-952 [Abstract]
Izuhara, Y., Nangaku, M., Inagi, R., Tominaga, N., Aizawa, T., Kurokawa, K., van Ypersele de Strihou, C., Miyata, T. (2005). Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering. J. Am. Soc. Nephrol. 16: 3631-3641 [Abstract] [Full Text]
Xue, H., Zhang, Y.-L., Liu, G.-S., Wang, H. (2005). A New ATP-Sensitive Potassium Channel Opener Protects the Kidney from Hypertensive Damage in Spontaneously Hypertensive Rats. J. Pharmacol. Exp. Ther. 315: 501-509 [Abstract] [Full Text]
Pohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerrari, G., Eisner, G., Esmatjes, E., Gilbert, R. E., Hunsicker, L. G., de Faria, J. B. L., Mangili, R., Moore, J. Jr., Reisin, E., Ritz, E., Schernthaner, G., Spitalewitz, S., Tindall, H., Rodby, R. A., Lewis, E. J., for the Collaborative Study Group, (2005). Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. J. Am. Soc. Nephrol. 16: 3027-3037 [Abstract] [Full Text]
J, X., G, L., P, W., H, V., X, Y., Y, L., Y, W., A, P., S, C., GV, D., H, I., MH, O., K, W., K, B.-J., LH, L., CE, M., B, D., RB, D., U, d. F., F, F., S, J., SE, K., O, L.-P., Nieminen, , P, O., S, O., Y, W., H, X., P, H., Z, L., D, H., P, H., N, M., RJ, F., JC, J. (2005). Kidney and Blood Pressure--The Story Unfolds: Renalase Is a Novel, Soluble Monoamine Oxidase That Regulates Cardiac Function and Blood Pressure. J Clin Invest. J. Am. Soc. Nephrol. 16: 2521-2527 [Full Text]
Chatziantoniou, C., Dussaule, J.-C. (2005). Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?. Am. J. Physiol. Renal Physiol. 289: F227-F234 [Abstract] [Full Text]
Fliser, D., Kronenberg, F., Kielstein, J. T., Morath, C., Bode-Boger, S. M., Haller, H., Ritz, E. (2005). Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study. J. Am. Soc. Nephrol. 16: 2456-2461 [Abstract] [Full Text]
Contreras, G., Greene, T., Agodoa, L. Y., Cheek, D., Junco, G., Dowie, D., Lash, J., Lipkowitz, M., Miller, E. R. III, Ojo, A., Sika, M., Wilkening, B., Toto, R. D., for the African American Study of Kidney Disease a, (2005). Blood Pressure Control, Drug Therapy, and Kidney Disease. Hypertension 46: 44-50 [Abstract] [Full Text]
Kanno, Y., Okada, H., Yamaji, Y., Nakazato, Y., Suzuki, H. (2005). Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM 98: 199-203 [Abstract] [Full Text]
Wu, D., Chen, X., Guo, D., Hong, Q., Fu, B., Ding, R., Yu, L., Hou, K., Feng, Z., Zhang, X., Wang, J. (2005). Knockdown of Fibronectin Induces Mitochondria-Dependent Apoptosis in Rat Mesangial Cells. J. Am. Soc. Nephrol. 16: 646-657 [Abstract] [Full Text]
Chiurchiu, C., Remuzzi, G., Ruggenenti, P. (2005). Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. J. Am. Soc. Nephrol. 16: S58-S63 [Abstract] [Full Text]
Esnault, V. L.M., Ekhlas, A., Delcroix, C., Moutel, M.-G., Nguyen, J.-M. (2005). Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents. J. Am. Soc. Nephrol. 16: 474-481 [Abstract] [Full Text]
Ibsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlof, B., Devereux, R. B., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wan, Y. (2005). Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202 [Abstract] [Full Text]
Jadoul, M (2005). Optimal care of lupus nephritis patients. Lupus 14: 72-76 [Abstract]
Artz, M. A., Hilbrands, L. B., Borm, G., Assmann, K. J. M., Wetzels, J. F. M. (2004). Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 19: 2852-2857 [Abstract] [Full Text]
Akbari, A., Swedko, P. J., Clark, H. D., Hogg, W., Lemelin, J., Magner, P., Moore, L., Ooi, D. (2004). Detection of Chronic Kidney Disease With Laboratory Reporting of Estimated Glomerular Filtration Rate and an Educational Program. Arch Intern Med 164: 1788-1792 [Abstract] [Full Text]
Chrysant, S. G., Chrysant, G. S. (2004). Pharmacological and Clinical Profile of Moexipril: A Concise Review. J Clin Pharmacol 44: 827-836 [Abstract] [Full Text]
Graciano, M. L., Cavaglieri, R. d. C., Delle, H., Dominguez, W. V., Casarini, D. E., Malheiros, D. M. A. C., Noronha, I. L. (2004). Intrarenal Renin-Angiotensin System Is Upregulated in Experimental Model of Progressive Renal Disease Induced by Chronic Inhibition of Nitric Oxide Synthesis. J. Am. Soc. Nephrol. 15: 1805-1815 [Abstract] [Full Text]
Eardley, K.S., Ferreira, M.A.S., Howie, A.J., Gosling, P., Lipkin, G.W. (2004). Urinary albumin excretion: a predictor of glomerular findings in adults with microscopic haematuria. QJM 97: 297-301 [Abstract] [Full Text]
Chen, X., Qiu, Q., Tang, L., Liu, S., Cai, G., Liu, H., Xie, Y. (2004). Effects of co-administration of urokinase and benazepril on severe IgA nephropathy. Nephrol Dial Transplant 19: 852-857 [Abstract] [Full Text]
Perlman, A., Lawsin, L. M., Kolachana, P., Saji, M., Moore, J. Jr., Ringel, M. D. (2004). Angiotensin II Regulation of TGF-{beta} in Murine Mesangial Cells Involves Both PI3 Kinase and MAP Kinase. Annals of Clinical & Laboratory Science 34: 277-286 [Abstract] [Full Text]
Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Iwasaka, T. (2004). Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus. CLIN APPL THROMB HEMOST 10: 133-141 [Abstract]
Chertow, G. M. (2004). A 43-Year-Old Woman With Chronic Renal Insufficiency. JAMA 291: 1252-1259 [Full Text]
Praga, M. (2004). Reply. Nephrol Dial Transplant 19: 747-748 [Full Text]
Matsuda, H., Hayashi, K., Wakino, S., Kubota, E., Honda, M., Tokuyama, H., Takamatsu, I., Tatematsu, S., Saruta, T. (2004). Role of Endothelium-Derived Hyperpolarizing Factor in ACE Inhibitor-Induced Renal Vasodilation in Vivo. Hypertension 43: 603-609 [Abstract] [Full Text]
Furberg, C. D., Psaty, B. M. (2003). Should Evidence-Based Proof of Drug Efficacy Be Extrapolated to a "Class of Agents"?. Circulation 108: 2608-2610 [Full Text]
van Dijk, M. A., Breuning, M. H., Duiser, R., van Es, L. A., Westendorp, R. G. J. (2003). No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18: 2314-2320 [Abstract] [Full Text]
Haroun, M. K., Jaar, B. G., Hoffman, S. C., Comstock, G. W., Klag, M. J., Coresh, J. (2003). Risk Factors for Chronic Kidney Disease: A Prospective Study of 23,534 Men and Women in Washington County, Maryland. J. Am. Soc. Nephrol. 14: 2934-2941 [Abstract] [Full Text]
Jafar, T. H., Schmid, C. H., Stark, P. C., Toto, R., Remuzzi, G., Ruggenenti, P., Marcantoni, C., Becker, G., Shahinfar, S., de Jong, P. E., de Zeeuw, D., Kamper, A.-L., Strangaard, S., Levey, A. S. (2003). The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 18: 2047-2053 [Abstract] [Full Text]
Weise, W. J (2003). Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non-diabetic renal disease. Evid. Based Med. 8: 143-143 [Full Text]
Praga, M., Andrade, C. F., Luno, J., Arias, M., Poveda, R., Mora, J., Prat, M. V., Rivera, F., Galceran, J. M., Ara, J. M., Aguirre, R., Bernis, C., Marin, R., Campistol, J. M. (2003). Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 18: 1806-1813 [Abstract] [Full Text]
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S., for the AIPRD Study Group*, (2003). Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. ANN INTERN MED 139: 244-252 [Abstract] [Full Text]
Feldman, H. I., Appel, L. J., Chertow, G. M., Cifelli, D., Cizman, B., Daugirdas, J., Fink, J. C., Franklin-Becker, E. D., Go, A. S., Hamm, L. L., He, J., Hostetter, T., Hsu, C.-y., Jamerson, K., Joffe, M., Kusek, J. W., Landis, J. R., Lash, J. P., Miller, E. R., Mohler, E. R. III, Muntner, P., Ojo, A. O., Rahman, M., Townsend, R. R., Wright, J. T. (2003). The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J. Am. Soc. Nephrol. 14: S148-153 [Abstract] [Full Text]
Gassman, J. J., Greene, T., Wright, J. T. Jr., Agodoa, L., Bakris, G., Beck, G. J., Douglas, J., Jamerson, K., Lewis, J., Kutner, M., Randall, O. S., Wang, S.-R. (2003). Design and Statistical Aspects of the African American Study of Kidney Disease and Hypertension (AASK). J. Am. Soc. Nephrol. 14: S154-165 [Abstract] [Full Text]
Yu, H. T. (2003). Progression of Chronic Renal Failure. Arch Intern Med 163: 1417-1429 [Abstract] [Full Text]
Stigant, C., Stevens, L., Levin, A. (2003). Nephrology: 4. Strategies for the care of adults with chronic kidney disease. CMAJ 168: 1553-1560 [Full Text]
Dandona, P., Aljada, A., Chaudhuri, A., Bandyopadhyay, A. (2003). The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 88: 2422-2429 [Full Text]
Tomlinson, J. W., Owen, K. R., Close, C. F. (2003). Treating Hypertension in Diabetic Nephropathy. Diabetes Care 26: 1802-1805 [Abstract] [Full Text]
Praga, M., Gutierrez, E., Gonzalez, E., Morales, E., Hernandez, E. (2003). Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial. J. Am. Soc. Nephrol. 14: 1578-1583 [Abstract] [Full Text]
Tonelli, M., Moye, L., Sacks, F. M., Cole, T., Curhan, G. C. (2003). Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease. J. Am. Soc. Nephrol. 14: 1605-1613 [Abstract] [Full Text]
Appel, G. B., Radhakrishnan, J., Avram, M. M., DeFronzo, R. A., Escobar-Jimenez, F., Campos, M.M., Burgess, E., Hille, D. A., Dickson, T. Z., Shahinfar, S., Brenner, B. M. (2003). Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study. Diabetes Care 26: 1402-1407 [Abstract] [Full Text]
Mann, J.F.E, Dulau-Florea, I, Franke, J (2003). Looking for people at high cardiovascular risk? Look at serum-creatinine. Eur Heart J 24: 381-383 [Full Text]
Hillege, H.L., van Gilst, W.H., van Veldhuisen, D.J., Navis, G., Grobbee, D.E., de Graeff, P.A., de Zeeuw, D. (2003). Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24: 412-420 [Abstract] [Full Text]

Comments and questions? Please contact us.